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Background: To evaluate the promoter methylation status of MUC2 gene and mRNA expression in patients with
hepatocellular carcinoma.
Methods: We analyzed MUC2 methylation by MSP, and MUC2 mRNA by real-time PCR in 74 HCC.
Results: MUC2 mRNA were lower in HCC tissues (Mean -ΔCt = −4.70) than that in Non-HCC tissues (Mean -ΔCt = −2.98).
Expression of MUC2 was elevated in only 23 (31.08%) of the 74 HCC patients. MUC2 promoter was hypermethylated in
62.2% (46/74) of HCCs, and in only 18.9% (14/74) of non-tumor samples. MUC2 mRNA were lower in HCC patients with
hypermethylation (Mean -ΔΔCt = −2.25) than those with demethylation (Mean -ΔΔCt = −0.22), and there is a decreased
tendency for MUC2 mRNA in HCC patients with promoter hypermethylation (p = 0.011). There was a significantly
correlation found between MUC2 mRNA and HBV and AFP in HCC. The loss of MUC2 mRNA and hypermethylation
could be poor prognostic factors. After treated by 5-Aza-CdR and TSA, we found that MUC2 mRNA induced
significantly in 7721, Huh7 and HepG2 cells.
Conclusion: The results suggested that MUC2 mRNA silenced by promoter hypermethylation is associated with high
levels HBV in HCC.
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Mucins are high molecular weight glycoprotein com-
ponents of mucus, which protect and lubricate the epi-
thelial surfaces of the respiratory, gastrointestinal and
reproductive tracts in the body. In humans, to date,
about six secreted and 14 membrane-tethered mucins
have been reported based on cloned complementary
DNA (cDNA) sequences [1,2].
MUC2 is the major secreted mucin in the large and
small intestine with an O-linked carbohydrate. MUC2
presents in normal gastrointestinal secretion products and
epithelia, and in some tumors [3]. Alteration of MUC2 ex-
pression may contribute to change in growth regulation,
immune recognition, cellular adhesion, carcinoma-host
and other cellular interactions, which may influence the* Correspondence: hbzcs@126.com
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reproduction in any medium, provided the orinvasive and metastatic capabilities of the cancer [4,5].
The aberrant expression of MUC2 is together with altered
expression of MUC5AC and MUC6 in intestinal metapla-
sia during the process of gastric carcinogenesis. And the
MUC2 expression pattern is a reliable marker of intestinal
metaplasia associated H. pylori infected individuals [6].
The increased MUC2 expression in intestinal metaplasia
in the neighborhood of the carcinomas may play an im-
portant role in gastric carcinomas or IPMN [7,8]. It has
been recently suggested that mucin genes have a regula-
tory role for their products during cell proliferation and
differentiation, and this leads to carcinogenesis when these
gene products are expressed inappropriately in the patho-
genesis of breast cancer, gastric carcinomas, etc. [1,9].
Human normal bile ducts do not show MUC2, and
MUC2 mRNA was detectable in the normal cholan-
giocytes. But the presence of MUC2 protein was not
demonstrable by immunohistochemical staining cholan-
giocarcinoma [10,11]. MUC2 expression were observedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The conventional intrahepatic cholangiocarcinoma (ICC)
frequently expressed MUC5AC, but no MUC2, in carcin-
oma cells. Therefore, the expression of MUC2 seems to be
a specific feature of mucinous ICC and Intraductal papil-
lary neoplasia of the liver [13]. Colonic epithelial meta-
plasia resembling regenerating colonic epithelia and/or
tubular adenoma of the colon also occur in hyperplastic
and dysplastic biliary lining epithelia in chronic biliary
disease and is positive for MUC2 and CK20 [14,15]. How-
ever, the results regarding correlations of MUC2 expres-
sion in cancer are contradictory [16].
Given that the aberrant expression of MUC2, it is
conceivable that MUC2 may be also involved in the de-
velopment of cellular differentiation in Hepatocellular
Carcinoma [17]. Relatively little is known, however,
about the mechanisms responsible for regulation of
MUC2 expression in HCC. MUC2 gene regulation
mechanism disclosed that DNA methylation and his-
tone modification in the 5’ flanking region of the MUC2
promoter may play an important role [4]. MUC2 are
highly submitted to DNA methylation and histone
modifications, and MUC2 repression by cell-specified
methylation is controlled by DNA methyltransferase 1
(DNMT1) and dramatically impairs their activation by
the transcription factor Sp1 in epithelial cancer cells
[18,19]. MUC2 expression in gastric cells is regulated by
promoter methylation with two specific CpG sites [20].
And the low methylation status of MUC2 gene plays a
predominant role in high level MUC2 expression in mu-
cinous colorectal cancer [21]. The histone H3 modifica-
tion could play an important role in MUC2 gene
expression, possibly affecting DNA methylation in pan-
creatic neoplasm [22]. It implied that the promoter
methylation of MUC2 could play a particularly important
regulatory role for MUC2 expression in carcinogenesis.
So far the few studies conducted focused on MUC2
methylation and no data are available regarding MUC2
in HCC. In this study, we examined the expression of
MUC2 with respect to the promoter methylation in
HCC.
Materials and methods
Patients and tissue samples
All of these cases were surgically resected from 74
patients with HCC, and were obtained from our
departments and affiliated hospitals. The tissues samples
were flash frozen in liquid nitrogen immediately after
surgical resection. The matched non-HCC tissues were
obtained from the liver >3 cm away from tumors and
were confirmed to be tumor-free by microscopic exam-
ination. The patients consisted of 65 men and 9 women,
ranging in age from 27 to 70 years (mean ± SD, 49.51 ±
11.12 years). All tumors were histologically diagnosed asHCC according to the Edmondson-Steiner classification
system [23]. Written informed consent was obtained
from each patient, and the protocol of the study was
approved by the local ethics committee of Soochow
University.
Cell culture and treatment
The HCC cancer cell lines (7721, Huh7 and Hep-G2)
were kept in our laboratory. The cells were cultured in
RPMI medium plus 10% fetal bovine serum in a humidi-
fied 37°C incubator containing 5% CO2. They were
plated and treated with final concentration of 10 μM
5-Aza-2’-deoxycytidine (5-Aza-CdR, Sigma, St. Louis,
MO, USA) and 400 ng/ml Trichostatin A (TSA, Sigma,
St. Louis, MO, USA). The fresh medium was changed
every 24 hours to maintain the 5-Aza-CdR and TSA
concentration. RNA was isolated 3 days after treatment.
DMSO was being a blank control.
Methylation analysis of MUC2
The bisulfite modification of DNA was done according
to described previously [24]. MUC2 methylation was
measured using a methylation-specific PCR assay as pre-
viously described [22]. Primers used were: unmethylated
MUC2 forward primer, 5’-TTATATAAGTTAGTGGT
TTTTTTGG-3’, reverse primer, 5’-AATCTAATCAAA
CTCCTTAACCCAC-3’ (217 bp); methylated MUC2 for-
ward primer, 5’-TTTATATAAGTTAGTGGTTTTTTCG
G-3’, reverse primer, 5’-AATCTAATCAAACTCCTTA
ACCCG-3’ (216 bp). The PCR products were separated
on 2% agarose gels and visualized using ethidium brom-
ide staining. The methylation index (MI) of MUC2 was
calculated by the following formula: 100 × methylated
reaction/(unmethylated reaction + methylated reaction).
ΔMI defined as MIHCC - MINon-HCC. Distilled water was
used as negative control, DNA methylated by SssI
methylase (Sss DNA) was used as positive control.
Quantitative real-time PCR analysis for MUC2
Total RNA was isolated from 74 HCC, adjacent normal
tissues, and cultured cells. The first-strand cDNA was
synthesized from 2 μg of total RNA. Primer sequences
of MUC2 for reverse transcription-PCR (RT-PCR) reac-
tion were forward (5’- CTTCGACGGACTCTACTAC
AGC-3’) and reverse (5’- CTTTGGTGTTGTTGCCA
AAC-3’) [25]. Quantitative real-time PCR (qPCR) were
carried out by using the M×3000P QPCR System
(Stratagene, California, USA). The cDNA was then used
for qPCR in a 20 μl SYBR Premix Ex Taq. qPCR for
MUC2 mRNA expression was performed under the
following conditions: 5 min at 95°C, 40 cycles of 30 -
seconds at 95°C, 30 seconds at 60°C, and 1 min at 72°C.
As an internal control for qPCR, β-actin mRNA expres-
sion was amplified from the same cDNA samples. All
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values for triplicate reactions were averaged and relative
MUC2 expression was determined with the comparative
CT method, using average CT values for MUC2 and
β-actin.
Statistical analysis
All data were generated without knowledge of the clin-
ical status of the samples analyzed by SPSS 17.0 software
(SPSS, Inc., Chicago, USA). Associations between cat-
egorical variables were examined by using the Pearson
χ2 and Fisher exact tests. Kaplan–Meier analysis and the
log rank test were performed to identify survival
differences in HCC. A P value of less than 0.05 was
considered statistically significant.
Results
The levels of MUC2 mRNA in HCC and corresponding
non-tumor tissues
To accurately quantify relatively MUC2 mRNA levels,
we used a real-time PCR assay in 74 HCC and matched
non-tumor tissues. Overall results of MUC2 mRNA are
summarized in Figure 1. We found that MUC2 mRNA
expression lower in HCC tissues (Mean -ΔCt = −4.70;
95% CI, -5.88 – -3.53) than that in Non-HCC tissues
(Mean -ΔCt = −2.98; 95% CI, -3.99 – -1.97). MUC2 expres-
sion was significantly difference between HCC tissues and
matching non-tumor tissues (p < 0.0001; Figure 1A).
There was a decreased tendency for MUC2 expression
from Non-HCC tissues to HCCs, and more HCC samples
showed lower MUC2 expression (Figure 1B). Expression
of MUC2 was elevated (−ΔΔCt > =0) in only 23 (31.08%)
of the 74 HCC patients but decreased (−ΔΔCt < 0) in 51
(68.92%) of the patients (Figure 1C). This would suggestFigure 1 MUC2 mRNA in HCC and the matched non-tumor liver tissu
Data are shown by the Mean -ΔCT and 95%CI. The MUC2 mRNA in HCC wa
(B) There was a decreased tendency for MUC2 expression from Non-HCC t
only 23 of the 74 HCC patients but decreased (−ΔΔCt < 0) in 51 of the patthat the loss of MUC2 gene expression is a critical re-
quirement for the development of HCC.
Association of MUC2 mRNA with clinicopathologic
features
The relationship between MUC2 mRNA status and
known clinicopathologic factors in 74 tumor tissues
were examined. Initially analyzed were the associations
between mRNA status and available clinical information
including age, gender, differentiation of the tumor, pres-
ence of hepatitis, presence of cirrhosis, tobacco, alcohol,
AFP. These analyses were summarized in Table 1.
Significantly, the lower MUC2 mRNA was found in
HCC patients with HBV > = 105 (copy/ml) than those
with HBV < 105 (copy/ml) (Mean -ΔCt ± SE, -6.69 ±1.08
and −3.69 ± 0.67, respectively) (p = 0.015). Meanwhile,
the MUC2 mRNA was decreased in tumor tissues with
age > = 40 years than those with age < 40 years in HCC
patients (Mean -ΔCt ± SE, -5.57 ± 1.89 and −1.29 ± 0.80,
respectively) (p < 0.001). But the MUC2 mRNA was
elevated in tumor tissues with AFP > = 30 (μg/l) than
those with AFP < 30 (μg/l) in HCC patients (Mean -ΔCt ±
SE, -3.73 ± 0.75 and −6.25 ± 0.94, respectively) (p = 0.040).
There was no other significant correlation found between
other clinicopathological factors and MUC2 mRNA in
Chinese HCC. These results implicated that HBV and age
could play an important role for the loss of MUC2 gene
expression in HCC.
Methylation status of MUC2 promoter in HCC and its
adjacent tissue
The methylation status of MUC2 promoter region was
analyzed as one of the putative regulatory mechanisms
of MUC2 mRNA expression in HCCs and their adjacentes. (A) The MUC2 mRNA was indicated in HCC and Non-HCC samples.
s lower than that in the matched non-tumor liver tissues (p < 0.0001).
issues to HCC. (C) Expression of MUC2 was elevated (−ΔΔCt > =0) in
ients. Statistical analyses were done using the paired t test.
Table 1 Correlation of clinicophthologic variables with
MUC2 mRNA in HCC
Variable No.(74) Mean-Δct (± SE) P value*
Gender Male 65 −4.63 (± 0.62) 0.722
Female 9 −5.27 (± 1.89)
Age(y) > = 40 59 −5.57 (± 0.67) < 0.001
< 40 15 −1.29 (± 0.80)
HBV history Yes 43 1.07 (± 0.65) 0.393
No 31 1.89 (± 0.68)
Differentiation G1 62 −4.61 (± 0.65) 0.733
G2-3 12 −5.17 (± 1.44)
Cirrhosis Yes 39 −4.22 (± 0.82) 0.391
No 35 −5.24 (± 0.86)
Tobacco Yes 33 −5.04 (± 0.88) 0.609
No 41 −4.43 (± 0.80)
Alcohol Yes 14 −4.01 (± 1.32) 0.572
No 60 −4.87 (± 0.66)
HBV (copy/ml) > = 105 25 −6.69 (± 1.08) 0.015
< 105 49 −3.69 (± 0.67)
AFP (μg/l) > = 30 45 −3.73 (± 0.75) 0.040
< 30 29 −6.25 (± 0.94)
* Statistical significance determined using the independent samples test.
Figure 2 The promoter methylation of MUC2 in HCC tissues
and non-tumor tissues by MSP. (A) Methylation of MUC2
promoter in HCC and corresponding non-carcinoma tissues. M,
hypermethylation; PM, partial methylation; U, unmethylation; (B)
Representative patterns of MUC2 promoter methylation. U, reaction
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methylated PCR product, the partial methylation contains
both methylated and unmethylated PCR products, and
the unmethylation contains only unmethylated product.
MUC2 promoter was hypermethylated in 62.2% (46/74) of
HCCs, and in 18.9% (14/74) of non-tumor samples; partial
methylated in 28.4% (21/74) vs. 62.2% (46/74); unme-
thylated in 9.4% (7/74) vs. 18.9% (14/74). The difference of
MUC2 methylation between the tumor and non-tumor
groups was statistically significant (p < 0.0001) (Figure 2A).specific for unmethylated DNA; M, reaction specific for methylated
DNA. MI, The methylation index. -ΔCt, - (CTMUC2 - CTβ-actin).Association of MUC2 methylation with MUC2 mRNA
expression in HCC and corresponding normal tissues
To test whether MUC2 promoter methylation in
HCC might be correlated with repression of MUC2
mRNA transcription, qPCR was used for the expres-
sion of MUC2 transcripts in all tissue samples
(Figure 2B). The levels of MUC2 mRNA expression were
significantly decreased in HCC samples with methylation
(ΔMI > =0) than in those with hypomethylation (ΔMI < 0)
(Mean -ΔCt ± SE, -2.25 ± 0.37 and −0.22 ± 0.61, respect-
ively; p = 0.007; Figure 3A). We found that MUC2 methy-
lation is correlated significantly with MUC2 mRNA
expression, and there is a decreased tendency for MUC2
mRNA in HCC patients with promoter hypermethylation
(R2 Linear = 0.087, P = 0.011; Figure 3B). The results
suggested that HCC showing hypermethylation of MUC2promoter is considered to be silencing MUC2 mRNA
expression.
The survival analysis associated with MUC2 mRNA and
methylation in HCC
The survival of these patients was compared by the
Kaplan–Meier method and the log rank test (Figure 4).
The MUC2 mRNA and promoter methylation was signifi-
cantly correlated with overall survival after surgery. We
found the decreased Expression of MUC2 (−ΔΔCt < 0)
were significantly correlated with poor overall survival
(p < 0.0001; HR = 0.238, 95% CI: 0.13-0.43; Figure 4A).
Results showed the cumulative survival after surgery in
HCC with ΔMI > =0 was significantly shorter than those
with ΔMI < 0 (p = 0.0001; HR = 3.404, 95% CI: 1.81-6.39;
Figure 3 MUC2 mRNA and promoter methylation in HCC
patients. (A) MUC2 mRNA expression were lower in HCC patients
with ΔMI > = 0 than those with ΔMI < 0. Statistical analyses were done
using the unpaired t test. (B) The scatter plots summarized relative
expression levels of MUC2 mRNA (−ΔΔCT) associated with relative
methylation index (ΔMI) in HCC patients. Statistical analyses were
done using Pearson correlation test. -ΔΔCT, - (ΔCTHCC-ΔCTNon-HCC);
ΔMI, MIHCC-MINon-HCC.
Figure 4 MUC2 mRNA and hypermethylation confers poor
prognosis in HCC. (A) Kaplan–Meier analysis of survival months
after surgery according to MUC2 mRNA level. (B) Kaplan–Meier
analysis of survival months after surgery according to MUC2
methylation index.
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and methylation level could be prognostic factors in HCC.
MUC2 mRNA by 5-Aza-CdR and TSA
To analyze the effects of epigenetic inhibitor on MUC2
gene expression, Real-time PCR analyses were performed
using HCC cancer lines (7721, Huh7 and Hep-G2) treated
with final concentration of 10 μM 5-Aza-CdR and 400 ng/
ml TSA. After normalizing mRNA levels to β-actin, a
5.9-9.4 ΔCt induction of MUC2 mRNA was detected after5-Aza-CdR treatment in 7721 and Huh7 cells, but no
change for Hep-G2 cells (Figure 5A). Additionally, qRT-
PCR assays found that the expression of MUC2 gene was
induced 2–13.4 ΔCt after TSA treatment in three cells.
For the 5-Aza-CdR + TSA treatment, we found that a 7–8
ΔCt induction of MUC2 mRNA was detected in 7721 and
Huh7 cells. Taken together, the above results suggested
that the expression of MUC2 can be activated by 5-Aza-
CdR or TSA, and the effect on MUC2 expression is very
various for different cells.
Meanwhile, we observed the effects of 5-aza-CdR and
TSA on promoter methylation of MUC2 gene by MSP.
According to MSP analysis, the MUC2 promoter was
found to be hypermethylated in 7721 and Huh7, but
partial methylation in HepG2 cells (Figure 5B). The
Figure 5 Effect of 5-aza-CdR and TSA on expression of MUC2
transcription in HCC cell lines. (A) The MUC2 mRNA was detected
by real-time PCR for 7721, Huh7, and HepG2 treated with 5-aza-CdR,
TSA, alone or combination. (B) It indicated that MUC2 demethylation
induced significantly by TSA or TSA in 7721, Huh7 and HepG2 cells.
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TSA treatment in three cells. However, it showed differ-
ent effects on MUC2 methylation. These data suggested
the demethylation of MUC2 promoter by epigenetic in-
hibitor could play an important role for reactivating gene
expression.
Discussion
MUC2, as a secretory mucin with a central region
composed of a tandem repeat sequences of 23 amino acids
each, plays an important role for a physiological barrier
against various aggressions of the underlying epithelia
[26]. Given the putative role of MUC2 in tumourigenesis,
understanding the mechanisms that regulate its activity is
critical for a complete understanding of MUC2 function
in HCC.
The results confirmed that MUC2 was lower expression
in HCC tissues than corresponding normal tissues by
Real-time PCR. Meanwhile, 23 of HCC patients were
elevated for MUC2 mRNA, and 51 cases were decreased
for MUC2 mRNA. MUC2 mRNA was a statistically sig-
nificant difference between HCC and non-HCC tissues.
However, the loss of MUC2 mRNA could play more com-
plex role in the pathogenesis of HCC. The regulatory
mechanism of the MUC2 gene is unclear. We found that
the frequency of MUC2 hypermethylation was 46 cases in
HCC samples and 14 cases in non-tumor tissues. The
MUC2 mRNA expression were significantly decreased in
HCC samples with hypermethylation (ΔMI > =0) than in
those with hypomethylation (ΔMI > =0). It was adecreased tendency for MUC2 mRNA in HCC patients
with promoter hypermethylation. The results suggested
that HCC showing hypermethylation of MUC2 promoter
is considered to be silencing MUC2 mRNA expression.
This study showed that MUC2 expression could be
regulated by DNA methylation in the promoter region in
HCC.
We found that there is a significantly correlation found
between MUC2 mRNA and HBV and AFP in HCC. In
particular, the decreased expression of MUC2 and
hypermethylation clearly identified patients with a poorer
prognosis. One possible explanation could be that high
level of HBV virus is an important factor to regulate
methylation of MUC2 promoter in hepatocarcinogenesis.
HBx was positively correlated with the DNMT1 and
DNMT3A at both the mRNA and protein level [27]. And
HBx expression could up-regulate DNMT1, DNMT3A1,
and DNMT3A2 activities and selectively promoted
hypermethylation of specific tumor suppressor genes [28].
But the reason in term of MUC2 hypermethylation is not
yet well understood.
Epigenetic is essential for not only the maintenance but
also the initiation of many tumor types. The epigenetic
inhibitors 5-Aza-CdR or TSA play an important role for
regulating transcriptional activity of related gene [29].
Quantitative RT–PCR analysis of HCC cells showed that
treatment with 5-Aza-CdR or TSA gave a different change
in MUC2 mRNA. The 5-Aza-CdR alone treatment was
more effective in 7721 and Huh7 than Hep-G2. The TSA
alone treatment was more effective in Huh7 and Hep-G2
than 7721. And the combination treatment was more ef-
fective for 7721 and Huh7 than Hep-G2 in increasing
MUC2 mRNA. Meanwhile, we observed the different
effects of epigenetic inhibitors on promoter demethylation
of MUC2 gene in three cells. The combination treatment
in Huh7 showed a little demethylation, which could be
due to individual differences of cancer cells by incubated
with 5-Aza-CdR and TSA together. The inhibitors of his-
tone deacetylation and DNA methylation could have a dif-
ferent synergistic effect of MUC2 mRNA on cancer cells.
These results suggested that DNA epigenetic modification
influence MUC2 gene expression.
Conclusions
MUC2 promoter hypermethylation is frequently observed
in HCC and is associated with loss of mRNA expression
and loss of MUC2 mRNA and promoter hypermethylation
is significantly correlated with worse survival in HCC.
There was a significantly correlation found between MUC2
mRNA and HBV and AFP in HCC. An understanding of
these intimately correlated epigenetic changes may be of
importance for predicting the outcome of patients with
MUC2. Further investigations regarding the role of MUC2
expression in HCC are necessary.
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